NCT00817011

Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 25 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.

Detailed description

The difficulties to treat depressed patients are 1)the patients don't respond to antidepressant is about 40% of which, and 2) The time lag is existed until the patients respond to antidepressant and show the treatment effects. If it is predicted the response of antidepressant in advance, it would be overcome such problems. Drug response generally is known to be related to the individual genetic information and the environmental factors. We are going to investigation about antidepressant response using these approaches.

Conditions

• Depression
• Antidepressant Drug Adverse Reaction

Interventions

Type	Name	Description
DRUG	SSRI treated group	Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
DRUG	non-SSRI treated group	Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose

Timeline

• Start date: 2006-04-01
• Primary completion: 2016-12-01
• Completion: 2018-03-01
• First posted: 2009-01-06
• Last updated: 2015-12-31

Locations

1 site across 1 country: South Korea